Stockscreener 앱 받기
2.90
0.54%
-0.03
전일 마감가:
$2.93
열려 있는:
$2.93
하루 거래량:
262.52K
Relative Volume:
0.33
시가총액:
$207.10M
수익:
-
순이익/손실:
$-104.08M
주가수익비율:
-2.0613
EPS:
-1.4069
순현금흐름:
$-89.91M
1주 성능:
+2.98%
1개월 성능:
+25.61%
6개월 성능:
+47.93%
1년 성능:
+39.44%
1일 변동 폭
$2.875
$2.995
1주일 범위
$2.585
$3.02
52주 변동 폭
$1.63
$3.65
엔카르타 Stock (NKTX) Company Profile
명칭
Nkarta Inc
전화
(925) 407-1049
주소
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
2.905 | 208.88M | 0 | -104.08M | -89.91M | -1.4069 |
VRTX
Vertex Pharmaceuticals Inc
|
423.69 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
709.60 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
801.00 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.74 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
296.26 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
엔카르타 Stock (NKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-09 | 개시 | Rodman & Renshaw | Buy |
| 2024-08-14 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-22 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-07-28 | 개시 | Needham | Buy |
| 2022-07-18 | 개시 | SVB Leerink | Outperform |
| 2022-03-11 | 개시 | Raymond James | Outperform |
| 2022-03-08 | 개시 | H.C. Wainwright | Buy |
| 2022-01-06 | 개시 | William Blair | Outperform |
| 2021-11-18 | 개시 | SMBC Nikko | Outperform |
| 2021-07-16 | 개시 | Oppenheimer | Outperform |
| 2020-08-04 | 개시 | Cowen | Outperform |
| 2020-08-04 | 개시 | Evercore ISI | Outperform |
| 2020-08-04 | 개시 | Mizuho | Buy |
| 2020-08-04 | 개시 | Stifel | Buy |
모두보기
엔카르타 주식(NKTX)의 최신 뉴스
NKTX stock up on upbeat regulatory update on lead autoimmune program - MSN
Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts - MarketBeat
NKTX Nkarta reports wider than expected Q4 2025 loss, shares fall nearly 3% on weak investor sentiment.AI Stock Signals - Newser
Nkarta (NASDAQ:NKTX) Stock Price Down 3.1%Here's Why - MarketBeat
[ARS] Nkarta, Inc. SEC Filing - Stock Titan
Executive pay, auditor and board elections on ballot at Nkarta (NKTX) 2026 virtual meeting - Stock Titan
NKTX (Nkarta Inc.) reports wider than expected Q4 2025 loss, shares jump nearly 16 percent on upbeat investor sentiment.Retail Trader Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Nkarta cell therapy trial may soon offer outpatient treatment option in AAV - ANCA Vasculitis News
Nkarta (NKTX) Stock Dividend Safety (Underperforming) 2026-04-20Crowd Trend Signals - Xã Thanh Hà
Nkarta (NKTX) Stock: Why It Could Change (In Focus) 2026-04-18Private Capital - Cổng thông tin điện tử Tỉnh Sơn La
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program - The Globe and Mail
Nkarta receives FDA agreement for outpatient NKX019 dosing By Investing.com - Investing.com India
Should I buy Nkarta (NKTX) - Zacks Investment Research
Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta wins FDA nod for new trial protocol (NKTX:NASDAQ) - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers - Sahm
NKTX: Pivot to off-the-shelf CAR-NK therapy in autoimmune diseases, with broad trials and strong cash runway - TradingView
Nkarta announces FDA agreement on outpatient dosing of NKX019 in autoimmune disease, expanding access to community rheumatology centers - marketscreener.com
Nkarta receives FDA agreement for outpatient NKX019 dosing - Investing.com
Nkarta Reports FDA Agreement on Outpatient Dosing of NKX019 - marketscreener.com
Nkarta targets 2-hour monitoring, not overnight stays, in cell therapy trials - Stock Titan
CEO Moves: Will Nkarta Inc stock benefit from M A2026 Investor Takeaways & Technical Pattern Alert System - baoquankhu1.vn
If You Invested $1,000 in Nkarta, Inc. (NKTX) - Stock Titan
Aug PostEarnings: Is Nkarta Inc stock suitable for long term investing2026 Big Picture & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Nkarta to Participate in Needham Virtual Healthcare Conference - Bitget
Ideas Watch: Does Nkarta Inc have declining or rising EPSGap Down & High Win Rate Trade Tips - baoquankhu1.vn
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Layoff Watch: What analysts say about Nkarta Inc stock2026 Technicals & Real-Time Buy Zone Alerts - baoquankhu1.vn
Is Nkarta (NKTX) Stock Good for Beginners | Price at $2.37, Up 2.16%Most Discussed Stocks - Newser
Nkarta, Inc. (NASDAQ:NKTX) Given Average Recommendation of "Hold" by Analysts - MarketBeat
[EFFECT] Nkarta, Inc. SEC Filing - Stock Titan
Nkarta (NASDAQ: NKTX) launches $100M ATM shelf via Stifel as sales agent - Stock Titan
NKTX Technical Analysis & Stock Price Forecast - Intellectia AI
Nkarta (NASDAQ:NKTX) Price Target Lowered to $12.00 at Mizuho - Defense World
NKTX PE Ratio & Valuation, Is NKTX Overvalued - Intellectia AI
Mizuho lowers Nkarta stock price target on sales ramp moderation - Investing.com
Mizuho lowers Nkarta stock price target on sales ramp moderation By Investing.com - Investing.com India
HC Wainwright Forecasts Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World
HC Wainwright Forecasts Nkarta's Q1 Earnings (NASDAQ:NKTX) - MarketBeat
Nkarta files $350M shelf offering, plans $100M ATM stock sale via Stifel - MSN
Nkarta (NASDAQ:NKTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
TD Cowen Maintains Nkarta(NKTX.US) With Buy Rating - Moomoo
Risk Hedge: Will Nkarta Inc stock go up in YEARPortfolio Performance Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
엔카르타 (NKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.83%
2.04%
자본화:
|
볼륨(24시간):